|
May 14
|
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
|
|
May 10
|
89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials
|
|
May 9
|
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 9
|
‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks
|
|
May 8
|
89bio to Participate in the BofA Securities 2024 Health Care Conference
|
|
May 2
|
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
|
|
Apr 17
|
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
|
|
Apr 5
|
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 3
|
89bio Inc CEO Rohan Palekar Sells 52,718 Shares
|
|
Mar 27
|
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
|
|
Mar 18
|
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
|
|
Mar 13
|
13 Best Biotech Stocks To Buy Under $20
|
|
Mar 12
|
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
|
|
Mar 8
|
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 5
|
89bio to Participate in the Leerink Partners Global Biopharma Conference
|
|
Mar 5
|
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
|
|
Mar 5
|
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
|
|
Mar 5
|
89BIO (ETNB) Just Overtook the 200-Day Moving Average
|
|
Mar 4
|
Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment
|
|
Mar 4
|
Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
|